Yu changyuan

Name

姓名

Yu changyuan

Gender

性别

Male

Photo

照片

College

学院

College of Life Science and Technology

Highest degree

最高学历

Doctor degree

Professional Title

职称

Professor

Discipline/Major

专业

Life Science

Research Area/Direction

招生研究方向

Biomedical

Email

邮箱

yucy@buct.edu.cn

Research Topics（no more than 100 words）研究方向

tumor immunology ,new drug development, multi-omics and molecular diagnostics.

1. Tumor Immunology

2. Molecular Diagnostics

3. Bioinformatics

Education Background 教育背景

Xiangya Medical College, Central South University,Ph. D

Work Experience 工作经历

2005.3-present   College of Life Science and Technology, Beijing University of ChemicalTechnology, Professor

2002.9-2005.2    Institute of Basic Theory for Chinese MedicineChina Academy of Chinese Medical Sciences ,Postdoc Associate

1992.10-1999.8  Institute of Materia Medica,Jiuzhitang Pharmaceutical Co. Ltd Director, Senior Engineer 

1984.8-1992.9    Xinjiang Malan Base Army Hospital Xinjiang, Military Medical Officer

Publications(no more than 10 representative publications) 发表文章

(1) Polymorphism analysis and supertype definition of swine leukocyte antigen class I molecules in three-way crossbred (Landrace, Duroc, and Yorkshire) pigs: implications for the vaccine development of African swine fever virus. Sci China Life Sci. 2020;63(10):1604-1607.

(2) A high-throughput single cell-based antibody discovery approach against the full-length SARS-CoV-2 spike protein suggests a lack of neutralizing antibodies targeting the highly conserved S2 domain. Brief Bioinform. 2022;23(3).

(3) Design and synthesis of cinnamic acid triptolide ester derivatives as potent antitumor agents and their biological evaluation. Bioorg Med Chem Lett. 2022;67:128760.

(4) Specific subsets of urothelial bladder carcinoma infiltrating T cells associated with poor prognosis. Sci Rep. 2023;13(1):12801.

(5) Increasing the glucose metabolism enhances the bioelectricity generation in microbial fuel cells. Acta Biochim Biophys Sin (Shanghai). 2022;54(10):1566-1567.

(6) Over-expressing NadA quinolinate synthase in Escherichia coli enhances the bioelectrochemistry in microbial fuel cells. Biol Open. 2023;12(3).

(7) High affinity monoclonal antibody targeting Siglec-15 for cancer immunotherapy. J Clin Transl Res. 2021;7(6):739-749.

(8) Imidazole modified Pt(iv) prodrug-loaded multi-stage pH responsive nanoparticles to overcome cisplatin resistance. Chem Commun (Camb). 2020;56(76):11271-11274.

(9) MnO(2) Decorated Metal-Organic Framework-Based Hydrogel Relieving Tumor Hypoxia for Enhanced Photodynamic Therapy. Macromol Rapid Commun. 2023;44(19):e2300268.

(10) Apurinic/apyrimidinic endonuclease triggered doxorubicin-releasing DNA nanoprism for target therapy. Cell Cycle. 2022;21(24):2627-2634.